HELPERBY THERAPEUTICS LTD has a total of 213 patent applications. It decreased the IP activity by 55.0%. Its first patent ever was published in 1999. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, environmental technology and organic fine chemistry are COGNATE 3 LLC, BIOSYNERGEN INC and SMART DRUG SYSTEMS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 43 | |
#2 | WIPO (World Intellectual Property Organization) | 30 | |
#3 | Canada | 24 | |
#4 | EPO (European Patent Office) | 24 | |
#5 | China | 18 | |
#6 | United States | 18 | |
#7 | Hong Kong | 8 | |
#8 | Japan | 8 | |
#9 | Australia | 6 | |
#10 | Hungary | 6 | |
#11 | Brazil | 5 | |
#12 | Republic of Korea | 5 | |
#13 | New Zealand | 5 | |
#14 | Mexico | 4 | |
#15 | Israel | 3 | |
#16 | South Africa | 2 | |
#17 | Colombia | 1 | |
#18 | Iceland | 1 | |
#19 | Norway | 1 | |
#20 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Environmental technology | |
#3 | Organic fine chemistry | |
#4 | Biotechnology | |
#5 | Medical technology | |
#6 | Basic materials chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Hu Yanmin | 127 |
#2 | Coates Anthony | 60 |
#3 | Coates Professor Anthony | 32 |
#4 | Coates Anthony Robert Milnes | 32 |
#5 | Dyke Hazel Joan | 20 |
#6 | Pallin Thomas David | 20 |
#7 | Stoddart Gerlinda | 13 |
#8 | Beck Petra Helga | 13 |
#9 | Brown Marc Barry | 13 |
#10 | Coates Anthony Rm | 11 |
Publication | Filing date | Title |
---|---|---|
GB202004207D0 | Combinations | |
GB201914847D0 | Combination | |
GB201913068D0 | Combination | |
GB201910787D0 | Pharmaceutical development | |
GB201910777D0 | Analytical method | |
GB201910468D0 | Method | |
GB201807046D0 | Combination | |
WO2018172733A1 | Combinations of polymyxins | |
GB201802249D0 | Method | |
GB201709193D0 | Combination | |
GB201616909D0 | Combination | |
GB201616014D0 | Combination | |
GB201612093D0 | Combination | |
GB201610869D0 | Combination | |
US2018214440A1 | Oral composition | |
GB201522799D0 | Combination | |
EP3233105A1 | Novel combination and use | |
WO2016097755A1 | Antimicrobial combinations and their use in the treatment of microbial infection | |
GB201521901D0 | Combination | |
GB201521771D0 | Formulation |